7 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2032. from the record
Of the 4 now held by other companies, 1 name Jubilant Therapeutics India Limited as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2032
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2036 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Mar 2032 · High confidence
Tricyclic Fused PYRIDIN-2-ONE Derivatives and Their Use as BRD4 Inhibitors
US 10,689,395
The newest of the three, granted 2020. It anchors the portfolio to 2036, later than anything else here.
Tricyclic Fused Derivatives of 1-(CYCLO)ALKYL PYRIDIN-2-ONE Useful for the Treatment of Cancer
US 10,689,390
The newest of the three, granted 2020. It anchors the portfolio to 2036, later than anything else here.
Process For The Preparation Of Azilsartan Medoxomil
US 9,233,955
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Jul 2034 · High confidence
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
now held by Jubilant Therapeutics India Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 12, 2027The maintenance fee for Process For The Preparation Of Azilsartan Medoxomil (US 9,233,955) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,233,955 | Process For The Preparation Of Azilsartan Medoxomil In force · High confidence | In force | High confidence | |
| US 9,346,760 | Process for the Preparation of (S)-(+)- or (R)-(-)-10-Hydroxy Dihydrodibenz[b,f]azepines by Enantioselective Reduction of 10,11-Dihydro-10-OXO-5H-DIBENZ[B,F]AZEPINES and Polymorphs Thereof In force · High confidence | In force | High confidence | |
| US 9,932,336 | Process for the Preparation of Apixaban and Intermediates Thereof In force · High confidence | In force | High confidence | |
| US 10,689,390 | Tricyclic Fused Derivatives of 1-(CYCLO)ALKYL PYRIDIN-2-ONE Useful for the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 11,319,326 | Tricyclic Fused Derivatives of 1-(CYCLO)ALKYL PYRIDIN-2-ONE Useful for the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,689,395 | Tricyclic Fused PYRIDIN-2-ONE Derivatives and Their Use as BRD4 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,267,820 | Tricyclic Fused PYRIDIN-2-ONE Derivatives and Their Use as BRD4 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 4 patents in force now held by others · 1 patent ended · 2 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.